| Style | Citing Format |
|---|---|
| MLA | Allahyari A, et al.. "Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5)." BMC Cancer, vol. 22, no. 1, 2022, pp. -. |
| APA | Allahyari A, Ehsanpour A, Najafi B, Ansarinejad N, Mehrzad V, Kalantari B, Raafat J, Ghadiany M, Shahi F, Gharib B, Moazed V, Khosravi A, Mirpour MH, Salari S, Mortazavizadeh S, Nekoyi A, Khani M, Sadeghi A, Gharib S, ... Najaf S (2022). Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5). BMC Cancer, 22(1), -. |
| Chicago | Allahyari A, Ehsanpour A, Najafi B, Ansarinejad N, Mehrzad V, Kalantari B, Raafat J, et al.. "Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5)." BMC Cancer 22, no. 1 (2022): -. |
| Harvard | Allahyari A et al. (2022) 'Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5)', BMC Cancer, 22(1), pp. -. |
| Vancouver | Allahyari A, Ehsanpour A, Najafi B, Ansarinejad N, Mehrzad V, Kalantari B, et al.. Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5). BMC Cancer. 2022;22(1):-. |
| BibTex | @article{ author = {Allahyari A and Ehsanpour A and Najafi B and Ansarinejad N and Mehrzad V and Kalantari B and Raafat J and Ghadiany M and Shahi F and Gharib B and Moazed V and Khosravi A and Mirpour MH and Salari S and Mortazavizadeh S and Nekoyi A and Khani M and Sadeghi A and Gharib S and Bary A and Mirzania M and Haghighat S and Razavi SM and Emami SAH and Hosseinzadeh M and Mirbolouk M and Sadighi S and Shahrasbi A and Esfahani A and Gity M and Anjidani N and Kaf H and Najaf S}, title = {Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5)}, journal = {BMC Cancer}, volume = {22}, number = {1}, pages = {-}, year = {2022} } |
| RIS | TY - JOUR AU - Allahyari A AU - Ehsanpour A AU - Najafi B AU - Ansarinejad N AU - Mehrzad V AU - Kalantari B AU - Raafat J AU - Ghadiany M AU - Shahi F AU - Gharib B AU - Moazed V AU - Khosravi A AU - Mirpour MH AU - Salari S AU - Mortazavizadeh S AU - Nekoyi A AU - Khani M AU - Sadeghi A AU - Gharib S AU - Bary A AU - Mirzania M AU - Haghighat S AU - Razavi SM AU - Emami SAH AU - Hosseinzadeh M AU - Mirbolouk M AU - Sadighi S AU - Shahrasbi A AU - Esfahani A AU - Gity M AU - Anjidani N AU - Kaf H AU - Najaf S TI - Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5) JO - BMC Cancer VL - 22 IS - 1 SP - EP - PY - 2022 ER - |